ArticleBMC microbiology2026
Gut microbiota-metabolite interactions in cisplatin-induced acute kidney injury in rats.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiota-associated metabolic networks in gut-kidney communication and renal immune regulation: mechanisms and therapeutic potential.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe interplay between the gut microbiota and metabolites in the early stages of cisplatin-induced acute kidney injury (AKI) remains largely unexplored, especially in the early stages. This study aimed to identify the gut microbiota and metabolomic characteristics following cisplatin-induced AKI and to investigate the underlying mechanisms involved.
resultsMale Wistar rats were randomly assigned to a control group (NC) or a cisplatin-induced AKI group (Cis). The gut microbiota composition was analysed using 16 S rRNA sequencing, and faecal metabolomic profiles were characterized using untargeted metabolomics (UPLC‒MS/MS). The relationships among serum creatinine (SCr), blood urea nitrogen (BUN), faecal metabolites, and the gut microbiota were investigated to identify potential biomarkers and therapeutic targets for AKI. The functional impact of the identified metabolites was further assessed in HK-2 human renal tubular epithelial cells using Cell Counting Kit-8 (CCK-8) and flow cytometry assays. Cisplatin administration induced significant dysbiosis of the gut microbiota, altering its composition. The Cis group was enriched in proinflammatory genera such as Enterococcus and Anaerostipes, whereas the NC group was enriched in potentially beneficial genera such as Brotonthovivens, whose abundance was negatively correlated with the SCr and BUN levels. Concurrently, 20 differential faecal metabolites, including elevated dehydroepiandrosterone (DHEA) and N-acetylaspartic acid (NAA), were significantly correlated with impaired renal function. Correlation network analysis further revealed intricate associations between specific bacterial abundances and metabolite levels: Enterococcus was positively correlated with DHEA and NAA but negatively correlated with adenosine, guanine, and linoleic acid, whereas Brotonthovivens exhibited the opposite pattern. Moreover, analysis of colonic tissue revealed significant downregulation of the expression levels of the tight junction proteins ZO-1 and occludin, indicating impaired intestinal barrier integrity. Based on these integrated in vivo findings, targeted in vitro validation in HK-2 cells demonstrated that adenosine significantly attenuated cisplatin-induced cytotoxicity and apoptosis, whereas NAA exacerbated these injuries.
conclusionsOur findings demonstrated that cisplatin-induced AKI significantly reshaped the gut microbiota and faecal metabolome in rats. This study demonstrates potential interactions between specific gut microbes and host metabolites during AKI progression, offering novel insights into the gut–kidney axis and highlighting potential microbial and metabolic targets for future therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.